Novalgin (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish the sensitisation of pain receptors and reset the hypothalamic temperature set‑point, providing both pain relief and fever reduction.

The appropriate dose of Novalgin is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and renal function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of metamizole in pregnancy and lactation has not been definitively established. Healthcare providers usually weigh potential benefits against possible risks before prescribing it to pregnant or nursing women.

To request Novalgin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novalgin (metamizole) belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct safety profile, notably a risk of agranulocytosis. Compared with paracetamol or ibuprofen, it may be chosen when those agents are ineffective or contraindicated, always under medical supervision.

Novalgin should be stored at ambient temperature, below 25 °C, in its original packaging. It must be kept away from moisture and direct sunlight to maintain product stability.

Novalgin is administered orally, typically as tablets or oral solution, and should be taken with or without food as directed by the prescriber. The exact method of administration depends on the formulation supplied.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, rash, or other adverse symptoms.

Novalgin should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, in patients with existing severe blood dyscrasias, and in those for whom the risk of agranulocytosis outweighs the therapeutic benefit. Clinical judgment is essential.